Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tenaya Therapeutics, Inc.TNYA · Entity 6506 | Director | May 28, 2026 | May 29, 2026 |
| bluebird bio, Inc.BLUE · Entity 78923 | Chief Strategy Officer | August 20, 2019 | August 21, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tenaya Therapeutics, Inc.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2036-05-27 | Direct | 120,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 120,000 · Balance 120,000 F1: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.
bluebird bio, Inc.
Report date August 20, 2019 · Filed August 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,921 |
Ending reported balance
After 2019-08-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-08-20 · Exercise / conversion · Acquired 500 · Balance 41,421 Row 2 · 2019-08-20 · Sale · Disposed 500 · Balance 40,921 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 16, 2019. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.47 · Expires 2024-03-03 | Direct | 9,521 |
Reported balance
After 2019-08-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-08-20 · Exercise / conversion · Disposed 500 · Balance 9,521 F2: This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 16, 2019.
F2: This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2017 Filed Nov 3, 2017 16:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001209191-17-059149 · doc4.xml · derivative · entry 6 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,585 Underlying: Common Stock · 35,000 shares Expires 2023-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013, April 1, 2013, May 1, 2013, and June 24, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, April 1, 2014, May 1, 2014, and July 1, 2014, respectively, with the remainder of the shares vesting in equal monthly installments over the following three years. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 16:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 974 | $153.10 | $149,115.31 |
DisclosureSEC source: 0001209191-17-059149 · doc4.xml · nonDerivative · entry 5 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,305 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F5 · price: The range of prices for the transaction reported on this line was $153.00 to $153.40. The average weighted price was $153.0958. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 16:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 7,789 | $152.30 | $1,186,281.84 |
DisclosureSEC source: 0001209191-17-059149 · doc4.xml · nonDerivative · entry 4 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,279 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F4 · price: The range of prices for the transaction reported on this line was $152.00 to $152.9250. The average weighted price was $152.3022. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 16:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 15,462 | $151.45 | $2,341,747.73 |
DisclosureSEC source: 0001209191-17-059149 · doc4.xml · nonDerivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,068 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F3 · price: The range of prices for the transaction reported on this line was $151.00 to $151.95. The average weighted price was $151.4518. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 16:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 10,775 | $150.46 | $1,621,180.64 |
DisclosureSEC source: 0001209191-17-059149 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,530 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F2 · price: The range of prices for the transaction reported on this line was $150.00 to $150.95. The average weighted price was $150.4576. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 16:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 35,000 | $5.50 | $192,514.00 |
DisclosureSEC source: 0001209191-17-059149 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 10, 2017 Filed Oct 11, 2017 16:37 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 4,900 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001209191-17-056639 · doc4.xml · derivative · entry 5 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,585 Underlying: Common Stock · 4,900 shares Expires 2023-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option to purchase shares of our common stock granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years. Read SEC document |
| October 10, 2017 Filed Oct 11, 2017 16:37 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 500 | $131.80 | $65,900.00 |
DisclosureSEC source: 0001209191-17-056639 · doc4.xml · nonDerivative · entry 4 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,305 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. Read SEC document |
| October 10, 2017 Filed Oct 11, 2017 16:37 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,600 | $130.27 | $208,424.80 |
DisclosureSEC source: 0001209191-17-056639 · doc4.xml · nonDerivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,805 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F3 · price: The range of prices for the transaction reported on this line was $130.00 to $130.55. The average weighted price was $130.2655. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 10, 2017 Filed Oct 11, 2017 16:37 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 2,800 | $129.43 | $362,399.24 |
DisclosureSEC source: 0001209191-17-056639 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,405 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F2 · price: The range of prices for the transaction reported on this line was $129.00 to $129.95. The average weighted price was $129.4283. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 10, 2017 Filed Oct 11, 2017 16:37 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 4,900 | $5.50 | $26,951.96 |
DisclosureSEC source: 0001209191-17-056639 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 16:07 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 4,900 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001209191-17-052583 · doc4.xml · derivative · entry 4 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,485 Underlying: Common Stock · 4,900 shares Expires 2023-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option to purchase shares of our common stock granted on January 16, 2013 with performance-based vesting criteria that were met as of April 1, 2013. The shares underlying these options vested as follows: 25% vested on April 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 16:07 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,418 | $126.43 | $179,279.58 |
DisclosureSEC source: 0001209191-17-052583 · doc4.xml · nonDerivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,305 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F3 · price: The range of prices for the transaction reported on this line was $126.05 to $126.70. The average weighted price was $126.4313. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 16:07 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 3,482 | $125.44 | $436,785.21 |
DisclosureSEC source: 0001209191-17-052583 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,723 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F2 · price: The range of prices for the transaction reported on this line was $125.00 to $125.8750. The average weighted price was $125.4409. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 16:07 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 4,900 | $5.50 | $26,951.96 |
DisclosureSEC source: 0001209191-17-052583 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:02 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001209191-17-051252 · doc4.xml · derivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,385 Underlying: Common Stock · 12,000 shares Expires 2023-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase shares of our common stock granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:02 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 12,000 | $125.01 | $1,500,091.20 |
DisclosureSEC source: 0001209191-17-051252 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,305 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F2 · price: The range of prices for the transaction reported on this line was $125.00 to $125.15. The average weighted price was $125.0076. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:02 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 12,000 | $5.50 | $66,004.80 |
DisclosureSEC source: 0001209191-17-051252 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 28, 2017 Filed Aug 30, 2017 16:17 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 1,250 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001209191-17-050706 · doc4.xml · derivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,385 Underlying: Common Stock · 1,250 shares Expires 2023-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase shares of our common stock granted on January 16, 2013 with performance-based vesting criteria that were met as of May 1, 2013. The shares underlying these options vested as follows: 25% vested on May 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years. Read SEC document |
| August 28, 2017 Filed Aug 30, 2017 16:17 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,250 | $107.06 | $133,826.38 |
DisclosureSEC source: 0001209191-17-050706 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,305 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F2 · price: The range of prices for the transaction reported on this line was $107.00 to $107.35. The average weighted price was $107.0611. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 28, 2017 Filed Aug 30, 2017 16:17 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 1,250 | $5.50 | $6,875.50 |
DisclosureSEC source: 0001209191-17-050706 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 16:03 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 1,250 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001209191-17-048741 · doc4.xml · derivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,635 Underlying: Common Stock · 1,250 shares Expires 2023-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase shares of our common stock granted on January 16, 2013 with performance-based vesting criteria that were met as of May 1, 2013. The shares underlying these options vested as follows: 25% vested on May 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 16:03 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,250 | $95.41 | $119,265.13 |
DisclosureSEC source: 0001209191-17-048741 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,305 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F2 · price: The range of prices for the transaction reported on this line was $95.00 to $95.80. The average weighted price was $95.4121. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 16:03 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 1,250 | $5.50 | $6,875.50 |
DisclosureSEC source: 0001209191-17-048741 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 16:15 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001209191-17-044890 · doc4.xml · derivative · entry 4 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,885 Underlying: Common Stock · 2,500 shares Expires 2023-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase shares of our common stock granted on January 16, 2013 with performance-based vesting criteria that were met as of May 1, 2013. The shares underlying these options vested as follows: 25% vested on May 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 16:15 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 57 | $100.50 | $5,728.50 |
DisclosureSEC source: 0001209191-17-044890 · doc4.xml · nonDerivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,305 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 16:15 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 2,443 | $99.88 | $243,995.11 |
DisclosureSEC source: 0001209191-17-044890 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,362 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F2 · price: The range of prices for the transaction reported on this line was $99.5000 to $100.3750. The average weighted price was $99.8752. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 16:15 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 2,500 | $5.50 | $13,751.00 |
DisclosureSEC source: 0001209191-17-044890 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 16:18 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001209191-17-039817 · doc4.xml · derivative · entry 5 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,236 Underlying: Common Stock · 2,500 shares Expires 2021-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vests over a four-year period, at a rate of twenty-five percent (25%) on May 16, 2012 and in 36 equal monthly installments thereafter. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 16:18 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 2 | $111.10 | $222.20 |
DisclosureSEC source: 0001209191-17-039817 · doc4.xml · nonDerivative · entry 4 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,305 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 16:18 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 579 | $110.42 | $63,930.57 |
DisclosureSEC source: 0001209191-17-039817 · doc4.xml · nonDerivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,307 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F3 · price: The range of prices for the transaction reported on this line was $110.05 to $111.00. The average weighted price was $110.4155. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 16:18 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,919 | $109.26 | $209,678.58 |
DisclosureSEC source: 0001209191-17-039817 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,886 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F2 · price: The range of prices for the transaction reported on this line was $108.90 to $109.75. The average weighted price was $109.2645. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 16:18 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 2,500 | $2.09 | $5,216.00 |
DisclosureSEC source: 0001209191-17-039817 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 16:21 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001209191-17-038537 · doc4.xml · derivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,736 Underlying: Common Stock · 2,500 shares Expires 2021-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vests over a four-year period, at a rate of twenty-five percent (25%) on May 16, 2012 and in 36 equal monthly installments thereafter. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 16:21 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 2,500 | $100.05 | $250,135.00 |
DisclosureSEC source: 0001209191-17-038537 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,305 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F2 · price: The range of prices for the transaction reported on this line was $100.00 to $100.25. The average weighted price was $100.0540. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 16:21 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 2,500 | $2.09 | $5,216.00 |
DisclosureSEC source: 0001209191-17-038537 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2017 Filed May 12, 2017 16:20 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 1,250 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001209191-17-031936 · doc4.xml · derivative · entry 4 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,385 Underlying: Common Stock · 1,250 shares Expires 2023-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option to purchase shares of our common stock granted on January 16, 2013 with performance-based vesting criteria that were met as of May 1, 2013. The shares underlying these options vested as follows: 25% vested on May 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years. Read SEC document |
| May 10, 2017 Filed May 12, 2017 16:20 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 3 | $89.43 | $268.30 |
DisclosureSEC source: 0001209191-17-031936 · doc4.xml · nonDerivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,305 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F3 · price: The range of prices for the transaction reported on this line was $89.40 to $89.45. The average weighted price was $89.4333. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 10, 2017 Filed May 12, 2017 16:20 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,247 | $88.77 | $110,698.06 |
DisclosureSEC source: 0001209191-17-031936 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,308 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F2 · price: The range of prices for the transaction reported on this line was $88.15 to $88.95. The average weighted price was $88.7715. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 10, 2017 Filed May 12, 2017 16:20 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 1,250 | $5.50 | $6,875.50 |
DisclosureSEC source: 0001209191-17-031936 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 16:12 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 1,250 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001209191-17-026664 · doc4.xml · derivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,635 Underlying: Common Stock · 1,250 shares Expires 2023-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase shares of our common stock granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 16:12 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,250 | $87.38 | $109,225.25 |
DisclosureSEC source: 0001209191-17-026664 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,305 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F2 · price: The range of prices for the transaction reported on this line was $87.05 to $87.90. The average weighted price was $87.3802. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 16:12 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 1,250 | $5.50 | $6,875.50 |
DisclosureSEC source: 0001209191-17-026664 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 16:06 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 266 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001209191-17-021693 · doc4.xml · derivative · entry 5 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,885 Underlying: Common Stock · 266 shares Expires 2023-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option to purchase shares of our common stock granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 16:06 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 3,277 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001209191-17-021693 · doc4.xml · derivative · entry 4 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,236 Underlying: Common Stock · 3,277 shares Expires 2021-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vests over a four-year period, at a rate of twenty-five percent (25%) on May 16, 2012 and in 36 equal monthly installments thereafter. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 16:06 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 3,543 | $100.07 | $354,563.24 |
DisclosureSEC source: 0001209191-17-021693 · doc4.xml · nonDerivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,305 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2015. F2 · price: The range of prices for the transaction reported on this line was $100.00 to $100.40. The average weighted price was $100.0743. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 16:06 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 266 | $5.50 | $1,463.11 |
DisclosureSEC source: 0001209191-17-021693 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 16:06 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 3,277 | $2.09 | $6,848.93 |
DisclosureSEC source: 0001209191-17-021693 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 16:32 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 58,300 | $0.00 Strike: $75.60 | $0.00 |
DisclosureSEC source: 0001209191-17-007620 · doc4.xml · derivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,300 Underlying: Common Stock · 58,300 shares Expires 2027-02-01 F2 · derivative.exercise_date: This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2018 and in 36 equal monthly installments thereafter. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 16:32 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 14,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-007620 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,305 F1 · security: Restricted stock units for common stock vest over a four-year period at a rate of 25% on 01/04/2018, 25% on 01/04/2019, 25% on 01/04/2020, and 25% on 01/04/2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.